Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing ...
Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...
Throughout this three-part webinar series, experts from USP and industry will share first-hand experiences, case studies, and ...
AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
The use of performance-enhancing drugs in sports is commonly referred by the term ‘doping’, particularly by those regulatory bodies overseeing sports that have made efforts to fight doping. Through ...
Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...
Plasmid DNA lies at the heart of viral and mRNA vector production because it provides the coding sequences for gene-based advanced therapy medicinal products (ATMPs). Its manufacture is therefore ...
Gene therapy using transiently expressed non-integrative plasmid vectors is the ideal solution for many public health applications. For example, no current therapy for diabetic foot ulcers directly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results